STOCK TITAN

Avalo Therapeutics: BVF attributed roughly 1.7% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. (AVTX) reported beneficial ownership positions held by three funds as of September 30, 2026: Biotechnology Value Fund, L.P. held 469,361 shares, Biotechnology Value Fund II, L.P. held 353,075 shares, and Biotechnology Value Trading Fund OS LP held 65,625 shares. Their affiliated entities and manager reported shared voting and dispositive power over related positions.

BVF Partners L.P., BVF Inc. and Mark N. Lampert, a director and officer of BVF Inc., each may be deemed to beneficially own 907,406 shares, or approximately 1.7% of the class; BVF GP Holdings LLC may be deemed to own 822,436 shares, or approximately 1.5%. The 907,406-share figure includes 19,345 shares in a Partners Managed Account. The ownership figures overlap through affiliated parties. Percentages are based on 53,629,989 shares outstanding as of August 3, 2026.

Biotechnology Value Fund shares 469,361 shares Beneficially owned as of September 30, 2026
Biotechnology Value Fund II shares 353,075 shares Beneficially owned as of September 30, 2026
Biotechnology Value Trading Fund OS shares 65,625 shares Beneficially owned as of September 30, 2026
Shares attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert 907,406 shares Each may be deemed to beneficially own this amount as of September 30, 2026
Shares attributed to BVF GP Holdings LLC 822,436 shares May be deemed beneficially owned as of September 30, 2026
Partners Managed Account shares 19,345 shares Included in the stated 907,406-share amount
Shares outstanding 53,629,989 shares As of August 3, 2026; used as the basis for ownership percentages
Ownership percentage attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert Approximately 1.7% As of September 30, 2026
beneficial ownership financial
"not be construed in and of itself as an admission"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power financial
"Shared Voting Power 469,361.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 469,361.00"
Partners Managed Account financial
"held in a certain Partners managed account"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AVTX shares did each BVF fund report owning?

As of September 30, 2026, Biotechnology Value Fund, L.P. reported 469,361 shares, Biotechnology Value Fund II, L.P. reported 353,075 shares, and Biotechnology Value Trading Fund OS LP reported 65,625 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





05338F306

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading